Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Allergen immunotherapy improves the quality of life of people who are allergic to grass pollen and house dust mites, reveals a study in the open access World Allergy Journal. With less time taken off work, the therapy yields economic as well as patient benefits.
Around a quarter of adults in Europe suffer from respiratory allergies. Symptoms can include asthma and / or rhino-conjunctivitis, inflammation of the inner nasal lining which causes a runny, stuffy nose. Treatment is usually with drugs, such as antihistamines, which manage the symptoms.
Allergen immunotherapy, however, seeks to treat the underlying cause. Subcutaneous immunotherapy, the type used in this study, involves regular injections with increasing doses of a specific allergen vaccine, then less frequent 'top-up' injections over several years.
Karin D Petersen and colleagues observed 248 allergy patients prospectively as they received the treatment for one year. As expected, disease severity lessened, but critically, this translated to significant improvements in quality of life. Sufferers experienced fewer symptom-filled days - 145 instead of 189 days per year - and took fewer sick days from work - 1.2 instead of 3.7.
This is likely to have knock-on effects for patients, employers and society, the team say. One US study found that allergic rhino-conjunctivitis causes an annual at-work productivity loss of around $2.5 billion. A separate study showed employees with allergic rhino-conjunctivitis suffer a productivity loss of around $593 per year.
But the real burden is personal, an element that is difficult to measure using traditional methods. Clinical symptoms, for example, correlate only modestly with everyday functional capabilities and patients' perceptions of their condition. The methods used in this study successfully measure personal quality of life as well as disease severity, highlighting the clinical and personal benefits to be gained from subcutaneous allergen immunotherapy.
Authors: Karin D Petersen, Christian Kronborg, J°rgen N Larsen, Ronald Dahl and Dorte Gyrd-Hansen
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Allergy category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Central, BioMed. "Improving the lives of allergy sufferers." Medical News Today. MediLexicon, Intl., 11 Sep. 2013. Web.
8 Dec. 2013. <http://www.medicalnewstoday.com/releases/265886>
Central, B. (2013, September 11). "Improving the lives of allergy sufferers." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265886.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.